Patent SG-11201901789W-A (SG)
Title: Anti-gm-csf antibodies and uses thereof
Inventor: WANG ZHENGYI
IPC: G01N33/68
Filed: 2017-09-18
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WIPO I PCT omit VIII °nolo III 0111100 oimIE (10) International Publication Number WO 2018/050111 Al (51) International Patent Classification: C07K 16/24 (2006.01) A61P 37/02 (2006.01) C12N 15/13 (2006.01) A61P 35/02 (2006.01) A61K 39/395 (2006.01) A61P 19/02 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). A61P 29/00 (2006.01) A61P 35/00 (2006.01) G01N 33/577 (2006.01) G01N 33/68 (2006.01) Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (21) International Application Number: PCT/CN2017/102057 (22) International Filing Date: 18 September 2017 (18.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201610831525.9 19 September 2016 (19.09.2016) CN 201610832677.0 19 September 2016 (19.09.2016) CN (71) Applicant: I-MAB [ /CN]; Suite 219, Building 6, Cham- time Plaza, 2889 Jingke Road, Shanghai 201206 (CN). (72) Inventors: WANG, Zhengyi; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). FANG, Lei; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). GUO, Bingshi; Suite 219, Building 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). ZANG, Jingwu; Suite 219, Build- ing 6, Chamtime Plaza, 2889 Jingke Road, Shanghai 201206 (CN). (74) Agent: SHANGHAI BESHINING LAW OFFICE; 21st Floor, SFECO Mansion, 681 Xiaomuqiao Road, Shanghai 200032 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) O O (54) Title: ANTI-GM-CSF ANTIBODIES AND USES THEREOF 00 (57) : Provided are anti-GM-CSF antibodies or fragments thereof including humanized antibodies and fragments. Also pro- O vided are uses of the antibodies and fragments for therapeutic, diagnostic and prognostic purposes. Therapeutic uses of the antibodies and fragments, for example include the treatment of inflammatory and autoimmune diseases and disorders. C